Corifollitropin alfa + hCG
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hypogonadotropic Hypogonadism
Conditions
Hypogonadotropic Hypogonadism
Trial Timeline
Feb 2, 2017 → May 5, 2020
NCT ID
NCT03019575About Corifollitropin alfa + hCG
Corifollitropin alfa + hCG is a phase 3 stage product being developed by Organon for Hypogonadotropic Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT03019575. Target conditions include Hypogonadotropic Hypogonadism.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03019575 | Phase 3 | Completed |
| NCT01709331 | Phase 3 | Completed |
Competing Products
3 competing products in Hypogonadotropic Hypogonadism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Investigational new drug company code: BGS649 + Placebo | Novartis | Phase 2 | 52 |
| BGS649 + Placebo | Mereo BioPharma | Phase 2 | 44 |
| BGS649 | Mereo BioPharma | Phase 2 | 44 |